Viatris (VTRS) Retained Earnings (2019 - 2026)
Viatris (VTRS) posted quarterly Retained Earnings of $18.7 billion for Q1 2026, down 1.57% year-over-year from $19.0 billion in Q1 2025, and down 0.73% quarter-over-quarter from $18.8 billion in Q4 2025.
Viatris (VTRS) Retained Earnings (2019 - 2026) Analysis & Trends
Viatris' Retained Earnings history runs 8 years deep, the most recent figure standing at $18.7 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 1.57% year-over-year to $18.7 billion; the TTM figure through Mar 2026 stood at $18.7 billion (down 1.57% YoY), while the FY2025 annual figure was $18.8 billion, down 0.64% from the prior year.
- Retained Earnings for Q1 2026 stood at $18.7 billion, down from $18.8 billion in the prior quarter.
- The five-year high for Retained Earnings was $19.0 billion in Q1 2025, with the low at -$3.8 billion in Q3 2022.
- The 5-year median for Retained Earnings is -$2.7 billion (2025), against an average of $6.1 billion.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings slumped 155.39% in 2022, then soared 781.4% in 2023.
- Viatris' Retained Earnings stood at -$2.8 billion in 2022, then surged by 781.4% to $18.8 billion in 2023, then climbed by 0.57% to $18.9 billion in 2024, then retreated by 0.64% to $18.8 billion in 2025, then declined by 0.73% to $18.7 billion in 2026.
- Business Quant data shows VTRS's Retained Earnings at $18.7 billion in Q1 2026, $18.8 billion in Q4 2025, and $18.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 3.75 Bn |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | -800.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.56 Bn |
| Mar 31, 2026 | 18.66 Bn |
| Dec 31, 2025 | 18.80 Bn |
| Sep 30, 2025 | 18.89 Bn |
| Jun 30, 2025 | -2.66 Bn |
| Mar 31, 2025 | 18.96 Bn |
| Dec 31, 2024 | 18.92 Bn |
| Sep 30, 2024 | 18.89 Bn |
| Jun 30, 2024 | -2.98 Bn |
| Mar 31, 2024 | -2.94 Bn |
| Dec 31, 2023 | 18.81 Bn |
| Sep 30, 2023 | -3.21 Bn |
| Jun 30, 2023 | -3.01 Bn |
| Mar 31, 2023 | -2.76 Bn |
| Dec 31, 2022 | -2.76 Bn |
| Sep 30, 2022 | -3.76 Bn |
| Jun 30, 2022 | -2.90 Bn |
| Mar 31, 2022 | -2.06 Bn |
| Dec 31, 2021 | -1.74 Bn |
| Sep 30, 2021 | -1.47 Bn |